Eris Lifesciences acquires 51% stake in Swiss Parenterals for ₹637.5 crore

Eris Lifesciences has acquired a 51% equity stake in Swiss Parenterals Ltd for ₹637.5 crore, with the promoter group acquiring an additional 19%, expanding into sterile injectables and RoW export markets.

“Eris Lifesciences Ltd., an Indian branded formulations company, on Tuesday announced the expansion of its Sterile Injectables footprint through the acquisition of 51 percent equity stake in Swiss Parenterals Ltd. for a consideration of Rs.637.50 crore.”financialexpress.com

• 1 source
• financialexpress.comEris Lifesciences acquires 51 percent stake in Swiss Parenterals to expand its footprint in sterile injectablesHealth DeskFeb 13, 2024

Summarized from public sources; check the original articles before acting on it.